Monoclonal antibodies in the treatment of advanced colorectal cancer

European Journal of Surgical Oncology

Volumn 33, Issue SUPPL. 2, 2007, Pages

  Capdevila, J ^a   Saura, C ^a   Macarulla, T ^a   Casado, E ^a   Ramos, F J ^a   Tabernero, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Monoclonal antibodies; Panitumumab; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VECTIBIX;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLEEDING; CANCER INHIBITION; CANCER INVASION; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; HYPERTENSION; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; THROMBOSIS; TREATMENT OUTCOME; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36749096406     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.09.025     Document Type: Review

References (64)

1. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
2. Alroy I., and Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410 (1997) 83-86
3. Burgering B.M., and Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376 (1995) 599-602
4. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 1 (2000) 12-21
5. Brabender J., Danenberg K.D., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7 (2001) 1850-1855
6. Steele R.J., Kelly P., Ellul B., and Eremin O. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 77 12 (1990) 1352-1354
7. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol 24 6 (1997) 602-615
8. Gill G.N., Kawamoto T., Cochet C., et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259 (1984) 7755-7760
9. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy. Clin Cancer Res 6 (2000) 747-753
10. Huang S.M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin Cancer Res 6 (2000) 2166-2174
11. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., and Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8 (2002) 994-1003
12. Saltz L.B., Rubin M., Hochster H., et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20 (2001) 3a
13. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
14. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
15. Saltz L., Kies M., Abbruzzese J.L., Azarnia N., and Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22 (2003) 204 [abstract 817]
16. Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study. ASCO Gastrointestinal Cancer Symposium, 2007 [abstract 237].
17. Wilke H., Glynne-Jones R., Thaler J., et al. MABEL - a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3549]
18. Souglakos J., Androulakis N., Tzardi M., et al. Cetuximab plus capecitabine (CAP) and oxaliplatin (LOHP) (CAPOX) as salvage treatment for patients with metastatic colorectal cancer (CRC) relapsing after oxaliplatin-based chemotherapy. ASCO Gastrointestinal Cancer Symposium (2006) [abstract 235]
19. Diaz-Rubio E., Tabernero J., Van Cutsem E., et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): an international phase II study. Proc Am Soc Clin Oncol 23 (2005) 16S [abstract 3535]
20. Colucci G., Giuliani F., Mattioli R., et al. FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot. GOIM 2402). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3559]
21. Venook A., Niedzwiecki D., Hollis D., et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) ± cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3509]
22. Borner M., Mingrone W., Koeberle D., et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3551]
23. Lang I., Zaluski J., Changchein C.R., et al. Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). Preliminary safety results (CRYSTAL). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3555]
24. Rosenberg A.H., Loehrer P.J., Needle M.N., et al. Erbitux (IMC-C225) plus weekly irinotecan, fluorouracil, and leucoverin in colorectal cancer that express the epidermal growth factor receptor. Proc Am Soc Clin Oncol 21 (2002) [abstract 536]
25. Folprecht G, Lutz M, Schefski P, et al. Cetuximab/irinotecan/high-dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). ASCO Gastrointestinal Cancers Symposium, 2004 [abstract 283].
26. Rougier P., Raoul J.-L., Van Laethem J.-L., et al. Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 22 (2004) 14S [abstract 3513]
27. Hohler T. Phase I/II study of cetuximab combined with 5-fluorouracil/leucovorin plus weekly oxaliplatin in first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer. Presented at the 30th European Society of Medical Oncology Congress, Vienna, Austria; October 29 to November 2004.
28. Dakhil S., Cosgriff T., Headley D., Badarinath S., and Boccia R.V. Cetuximab + FOLFOX6 as first-line therapy for metastatic colorectal cancer. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3557]
29. Tabernero J., Cervantes A., Martinelli E., et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3085]
30. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
31. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 (2005) 5235-5246
32. Hecht J., Patnaik A., Malik I., et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Proc Am Soc Clin Oncol 22 (2004) 14S [abstract 3511]
33. Van Cutsem E, Peeters M, Siena S, et al. Panitumumab significantly improves progression-free survival in patients with metastatic colorectal cancer. World Congress on Gastrointestinal Cancer, 2006 [abstract O-027].
34. Vanhoefer U., Tewes M., Rojo F., et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22 (2004) 175-184
35. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2 10 (2002) 795-803
36. Jain R.K. Molecular regulation of vessel maturation. Nat Med 9 6 (2003) 685-693
37. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 5 (2005) 1011-1027
38. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20 21 (2002) 4368-4380
39. Gray M.J., Wey J.S., Belcheva A., et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 65 9 (2005) 3664-3670
40. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 6423 (1993) 841-844
41. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 5 (1995) 1029-1039
42. Manley P.W., Martiny-Baron G., Schlaeppi J.M., and Wood J.M. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 11 12 (2002) 1715-1736
43. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 8 (2000) R15-R24
44. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
45. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 16 (2005) 3697-3705
46. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
47. Giantonio B.J., Levy D.E., O'Dwyer P.J., Meropol N.J., Catalano P.J., and Benson III A.V. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann Oncol 17 9 (2006) 1399-1403
48. Kopetz S., Eng C., Adinin R.B., et al. Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3579]
49. Sobrero A., Carrion R.P., Chiara S., et al. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3544]
50. Fuchs C., Marshall J., Mitchell E., et al. A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3506]
51. Giantonio B., Catalano P.J., Meropol N.J., et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc Am Soc Clin Oncol 23 (2005) 1S [abstract 2]
52. Cassidy J., Diaz Rubio E., Scheithauer W., et al. First efficacy and safety results from XELOX-1/NO16966, a randomised 2 × 2 factorial phase III trial of XELOX vs. FOLFOX4 1 bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Ann Oncol 17 Suppl. 9 (2006) [abstract LBA3]
53. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). ASCO Gastrointestinal Cancer Symposium, 2007 [abstract 238].
54. Hochster H.S., Hart L.L., Ramanathan R.K., Hainsworth J.D., Hedrick E.E., and Childs B.H. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3510]
55. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3536]
56. Berry S.R., Cunningham D., Michael M., et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC - first B.E.A. Trial. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3534]
57. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24 21 (2006) 3354-3360
58. Ciardello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 (2000) 3739-3747
59. Saltz L.B., Lenz H., Hochster S., et al. Randomised phase II study of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 23 (2005) 16S [abstract 3508]
60. Baselga J., Schöffski P., Rojo F., et al. A phase I pharmacokinetic and molecular pharmacodynamic of the combination of two anti-EGFR therapies, the monoclonal antibody cetuximab, and the tyrosine kinase inhibitor gefitinib, in patients with advanced colorectal, head and neck, and non-small cell lung cancer. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3006]
61. Julie C, Lutz MP, Aust D, et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC intergroup phase III study 40983. ASCO Gastrointestinal Cancer Symposium, 2007 [abstract 241].
62. Gruenberger B., Scheithauer W., Tamandl D., et al. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3546]
63. Bendell J.C., Fernando N., Morse M., et al. A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer. Proc Am Soc Clin Oncol 24 (2006) 18S [abstract 3541]
64. Kabbinavar F., Schultz J., McCleod M., et al. Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression-free survival in first-line colorectal cancer in subjects who are not suitable candidates for first-line CPT-11. Proc Am Soc Clin Oncol 22 (2004) 14S [abstract 3516]